Key Program of the National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81830008]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81670152, 81600120, 81873427]; Natural Science Foundation of Hubei ProvinceNatural Science Foundation of Hubei Province [2018ACA140, 2016CFA011]; Huanghe Talents Plan of Wuhan City grant [HHYC-2015002]; National High Technology Research and Development Program of China 863National High Technology Research and Development Program of China [2014AA020532]; Milstein Medical Asian American Partnership Foundation (2018 MMAAP Foundation Hematology Fellowship Award); Applied Basic Research Project of Wuhan City grant [2017060201010156]
第一作者单位：[1]Huazhong Univ Sci & Technol, Tongji Hosp, Dept Hematol, Tongji Med Coll, 1095 Jiefang Ave, Wuhan, Hubei, Peoples R China;[2]Immunotherapy Res Ctr Hematol Dis Hubei Prov, Wuhan, Hubei, Peoples R China;
通讯作者：
通讯机构：[1]Huazhong Univ Sci & Technol, Tongji Hosp, Dept Hematol, Tongji Med Coll, 1095 Jiefang Ave, Wuhan, Hubei, Peoples R China;[2]Immunotherapy Res Ctr Hematol Dis Hubei Prov, Wuhan, Hubei, Peoples R China;
推荐引用方式(GB/T 7714)：
Cao Wenyue,Wei Jia,Wang Na,et al.Entecavir prophylaxis for hepatitis B virus reactivation in patients with CAR T-cell therapy[J].BLOOD.2020,136(4):516-519.doi:10.1182/blood.2020004907.
APA：
Cao, Wenyue,Wei, Jia,Wang, Na,Xu, Hao,Xiao, Min...&Huang, Liang.(2020).Entecavir prophylaxis for hepatitis B virus reactivation in patients with CAR T-cell therapy.BLOOD,136,(4)
MLA：
Cao, Wenyue,et al."Entecavir prophylaxis for hepatitis B virus reactivation in patients with CAR T-cell therapy".BLOOD 136..4(2020):516-519
医学